Furthermore, other phase I clinical trials have addressed the efficacy of CAR-T cells targeting CEA as a regional treatment for liver metastases (NCT01373047, NCT02416466) from CRC. The gene discussed is CEACAM5; the disease is colorectal carcinoma.